Product Images Lactulose Solution

PSRising NDC 64980-592-48 is a lactulose solution that can be administered orally or rectally for the prevention and treatment of encephalopathy. It contains 10 g of lactulose per 15 mL and several colors, including D&C Yellow No. 10, FD&C Yellow No. 6, and purified water. It is recommended to mix it with fruit juice, water, or milk for better acceptance. The solution may darken slightly over time but is still effective. It should be dispensed by a pharmacist in a tightly sealed, light-resistant container and stored at controlled room temperature. The prescribing information is available in full. Distributed by Rising Pharmaceutical, Inc.*

Lactulose Solution USP is a medication for oral or rectal administration, used to prevent and treat portal-systemic encephalopathy. It is made of synthetic isaccharide in solution form, with each 15 mL containing 10 g lactulose and other solutions. Lactulose causes a decrease in blood ammonia concentration and reduces the degree of portal-systemic encephalopathy by decreasing the concentration of ammonia in the colon. Lactulose is poorly absorbed and mostly remains in the colon. Lactulose souton therapy reduces the biood ammonia level by 25 to 50%, and an increase in patients' protein tolerance is also frequently observed. However, it should be used with caution in diabetes and pregnant women.*

LACTULOSE SOLUTION, USP is indicated and administered orally or rectally for prevention and treatment of constipation. Each 15ml tablespoonful contains 10 aculose and other ingredients. This product is to be dispensed in a tight, light-resistant container and stored at a temperature between 20-25°C. It is distributed by Rising Pharmaceuticals.*

Lactulose Solution USP is a synthetic disaccharide and it is administered orally or rectally for the prevention and treatment of portal-systemic encephalopathy. It reduces blood ammonia and it is poorly absorbed by the body. Lactulose is metabolized by bacteria in the colon, forming low molecular weight acids that acidify the colon contents. It is contraindicated for patients requiring a low galactose diet, and caution is recommended for patients with diabetes. Lactulose should be used with caution in pregnant and nursing women as there is not enough evidence available on its safety. Patients undergoing electrocautery procedures during proctoscopy or colonoscopy while on lactulose therapy are advised to have thorough bowel cleansing with non-fermentable solution. Other drug interactions and possible side effects are mentioned in the text.*

Lactulose Solution, USP is indicated for the prevention and treatment of portal-systemic encephalopathy. It can be administered orally at a dosage of two to three tablespoons (containing 20-30 g of lactulose) a day for adults, or rectally via retention enema. The solution should be dispensed in a tight, light-resistant container and stored at 20-25°C. Adverse reactions may include diarrhea, abdominal discomfort, nausea, and vomiting. However, further data on lactulose use in pediatric patients is unavailable. The recommended initial dose for infants is 25-30mL, while older children and adolescents may be given a total daily dose of 40-90mL. In case of overdose, medication should be terminated, and when necessary, the patient may be given dialysis.*

FeRising NDC 64980-592-1 is a lactulose solution, USP, used for the prevention and treatment of portal-systemic encephalopathy. It contains 10g lactulose, less than 1.6g galactose, less than 1.2g lactose, and 0.1g or less of fructose in each 15mL, and should be stored at 20-25°C. The product may darken slightly but therapeutic action is not affected. It should be dispensed in a tight, light-resistant container as defined in the USP, with child-resistant closure. For more information, see the full Prescribing Information.*

Lactulose Solution USP is a synthetic disaccharide solution used for oral or rectal administration for the prevention and treatment of portal-systemic encephalopathy. Each 15 mL of the solution contains 10 g of lactulose and is essentially unchanged before reaching the colon, where it is metabolized by bacteria. Clinical studies have shown that lactulose solution therapy reduces blood ammonia levels by 25% to 50% and improves mental state and EEG patterns in about 75% of patients. The solution is contraindicated in patients who require a lactose-free diet.*

Lactulose solution is a medication used to treat portal-systemic encephalopathy, but patients being treated with the solution must be cautious during electrocautery procedures, as accumulation of gas alongside an electrical spark can lead to an explosive reaction. Thus, these individuals should have a thorough bowel cleansing beforehand. Lactulose solution contains galactose and lactose, so it should be used with care in individuals with diabetes. Infants may develop hyponatremia and dehydration after taking lactulose. There is conflicting information on the use of neomycin and lactulose, while non-absorbable antacids consumed with lactulose may inhibit the medication's desired effects. Using other laxatives is not recommended, especially in the early phase of therapy. No long-term potential for carcinogenicity, mutagenicity, or fertility impairment is known. Studies conducted in mice, rabbits, and rats indicate no impairment of fertility or teratogenic effects. While there are no well-controlled studies in pregnant women, lactulose should be used during pregnancy only when the benefits outweigh the risks.*

This text provides information on the use of lactulose in nursing mothers and pediatric patients. It cautions on the lack of information on adverse reactions and frequency data. Lactulose is known to produce gastrointestinal symptoms such as diarrhea and cramping. Dosage and administration guidelines are provided for oral and rectal use and should be followed carefully to avoid complications.*

Lactulose Solution, USP, is a medication used for the prevention and treatment of portal-systemic encephalopathy. It is supplied in clear, yellow to golden-yellow solution form for oral or rectal administration and can be found in 4-ounce (118 ml), 8-ounce (236 ml), 1-pint (473 ml), and 32-ounce (946 ml) bottles. The solution contains 667 mg lactulose/mL (10 g/15 mL), and it is stored in a tightly closed container between 20-25°C (68-77°F) to maintain its therapeutic action. While normal darkening of the color may occur under recommended storage conditions, extreme darkening and turbidity may be pharmaceutically objectionable, and the solution should not be used in such cases. The Rising Pharmaceuticals, Inc. distributes the solution with child-resistant closure.*

This is a description of a lactulose solution manufactured by P Rising. It is used for the prevention and treatment of portal-systemic encephalopathy and can be administered orally or rectally. Each 15mL tablespoonful contains 10g lactulose and small amounts of other sugars. The solution may be mixed with water, fruit or milk for better absorption. It should be stored at room temperature and in a light-resistant container. It comes in an 8oz (236 ml) bottle and has a prescribing information available.*

Lactulose Solution USP is a synthetic disaccharide solution for oral or rectal administration used for the prevention and treatment of portal-systemic encephalopathy. Each 15 mL of Lactulose Solution USP contains 10 lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 0.1 or less f fructose. Lactose is a colonic acidifier for the treatment and prevention of portal-systemic encephalopathy. The chemical name for lactulose is 4-0-§-D-galactopyranose-D-Tructofuranose. Lactulose therapy reduces the blood ammonia level by 25 to 50% and generally improves the patient's mental status and EEG pattern. Lactulose Solution USP is contraindicated in patients requiring a low galactose diet.*

Lactulose solution is a medication that is used to treat portal-systemic encephalopathy. It contains galactose and lactose and caution must be taken when using it on diabetic patients. Patients being treated with lactulose solution and undergoing electrocautery procedures during proctoscopy or colonoscopy may be at risk of an explosive reaction due to the accumulation of H, gas. Therefore, a thorough bowel cleansing with a non-fermentable solution is recommended. Infants receiving lactulose may develop hyponatremia and dehydration. There have been conflicting reports about the concomitant use of neomycin and lactulose solution. Preliminary studies suggest that concurrent use of nonabsorbable antacids with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Lactulose has no known long-term potential for carcinogenicity, mutagenicity, or impairment of fertility. It is not known if lactulose solution passes into breast milk. Therefore, women who are pregnant or breastfeeding should consult with their healthcare provider before using lactulose solution.*

This text provides information on the use of lactulose as a medication for pediatric and adult patients with liver disease. It includes dosing information, administration instructions for oral and rectal use, and possible adverse effects such as diarrhea and dehydration. The text mentions that caution should be taken when administering lactulose to nursing mothers, and that information on lactulose use in children is limited. However, the text does not provide information on the overall safety and efficacy of lactulose, nor does it indicate which liver diseases lactulose is most useful for.*

Lactulose Solution is a medication used for the prevention and treatment of portal-systemic encephalopathy. It comes in a clear, yellow to golden-yellow solution and is available in 4-ounce (118 ml) amber plastic bottle, 8-ounce (236 mi) white plastic bottle, 1-pint (473 ml) amber plastic bottle, 32-ounce (946 ml) white plastic bottle. It contains 667 mg lactulose/mL (10 g/15 mL). The storage should be at 20-25°C (68-77°F) and should not be frozen, and a normal darkening of color may occur under recommended storage conditions. Lactulose solution may be more acceptable when mixed with water or milk. It should be dispensed in a tight and light-resistant container with a child-resistant closure.*

This appears to be a chemical formula, specifically for a molecule that has 2 hydroxyl (OH) groups bonded to a central carbon atom (C), with the overall structure represented as CH20H.*